Consumer health · Teledermatology
Dear Brightly
A subscription that turns three selfies into a compounded tretinoin serum in the mail. Nine years in, the evidence record is a pharmacy formula and a state licence map, not a trial.
A remark in an engineering meeting
Amy Chiu had clear skin her whole life. In her mid twenties that stopped: hormonal acne, sun spots, uneven tone. Then a colleague remarked on it during a meeting.
She waited months for her first dermatologist appointment, paid about $200 out of pocket, was looked at for five to ten minutes, and left with tretinoin samples and no instructions. She used it in the morning. Her face burned.
“I used it incorrectly. Used it in the morning versus at night. I had a terrible reaction, redness, irritation, major skin peeling and I stopped it immediately.”
Months later a second dermatologist prescribed the same molecule and printed out directions.
“The difference was she wrote out very clear instructions on how to use it. And my skin changed from night and day.”
The gap between the drug and the instructions is the whole company.
The gap it is aimed at
Tretinoin is neither new nor exotic. Generic tretinoin cream 0.025% is an approved generic with its own application on file, indicated for acne vulgaris. Dear Brightly goes further, calling tretinoin the only FDA approved retinoid for photoaging. That is a company claim, and the category rests on it.
Access is the bottleneck. Chiu told a Target Accelerators interviewer: “we learned the surprising truth that for every 34,000 Americans, there’s one dermatologist”. The New York Times priced the other side in 2023: a tube of Retin-A can cost $100 to $200 at a pharmacy.
Two engineers and a spreadsheet
Chiu was an engineer at Optimizely. She and her co-founder, whom she names in interviews as Alda, built the service nights and weekends. “We were just working on manual spreadsheets at the time and then also building the site in parallel,” she told the podcast Brand Architects in 2025.
They applied to Y Combinator with seven paying customers, and got into the Winter 2018 batch. TechCrunch covered them that March, and the two operating facts in that piece still define the company: “DearBrightly only works with PCAB-accredited pharmacies, and is currently only operational in California, as laws vary from state to state.” The first year was one-off purchases; customers asked to be resupplied without asking, and it became a subscription.
What a tailored formula means in law
Night Shift is not an approved drug and is not trying to be. It is a compounded preparation, mixed against a prescription written for one named patient. Section 503A of the Federal Food, Drug, and Cosmetic Act exempts such preparations from premarket approval, from adequate directions labeling and from the manufacturing rules that bind approved drugs, on conditions. One is that the pharmacist “does not compound regularly or in inordinate amounts (as defined by the Secretary) any drug products that are essentially copies of a commercially available drug product.”
The statute then supplies the door. The phrase does not cover a product carrying “a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner”. Every personalized prescription skincare company walks through it.
FDA’s 2018 guidance marks out how narrow the door is. Quoting the congressional record, a compounded drug can still be essentially a copy where “minor changes in strength (such as from .08% to .09%) are made that are not known to be significant”. And to rely on a prescriber’s finding, “the compounder should ensure that the determination is documented on the prescription.”
Dear Brightly’s numbers sit inside that zone. Its FAQ lists “Night Shift: Niacinamide, Tretinoin (strengths range from 0.015% to 0.089%)”, in a silicone elastomer base. A 2021 review listed an older version with a different base and a wider range: “Night Shift: Hyaluronic Acid, Tretinoin (strengths range from 0.015% to 0.1%)”. The ceiling came down from 0.1%, a strength approved products carry, to 0.089%, which they do not. Nothing public explains why, or shows what any one prescription says.
Price, states and who is responsible
The offer is a $66 trial bottle lasting about two months, then $99 a quarter. Prescription service reached 31 states as of a 2021 review; the FAQ says only that the company is “limited by telehealth regulations and only service certain states in the US”. The terms of use are precise about where the doctoring sits: “Dear Brightly provides technological and other services to connect patients to licensed medical providers, but does not provide any medical services.”
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| FDA and trial records | No 510(k), PMA or approved application under any of the company’s names. No registered trial and no PubMed paper, as of September 2026. | Not found |
| Federal grants | No NIH or NSF award. The one NSF hit on the name is a 2023 biology fellowship to an unrelated awardee, William Brightly. | Record |
| Statutory basis | Section 503A exempts a compounded drug from approval only where the compounder avoids regularly making essentially copies of marketed products, unless a prescriber documents a change producing a significant difference for that patient. | Public record |
| How small a change can be | FDA’s 2018 guidance names a move from .08% to .09% as a change that may still leave a drug essentially a copy, and says the determination belongs on the prescription. | Public record |
| Published strengths | FAQ: tretinoin 0.015% to 0.089% with niacinamide. A 2021 review of the earlier formula listed 0.015% to 0.1% with hyaluronic acid. Whether prescriptions carry FDA-described documentation is not public. | Company-stated |
| The pharmacy | TechCrunch reported in 2018 that only PCAB-accredited pharmacies were used. The FAQ now says only “our preferred pharmacy”. Its name, and whether it is a 503A pharmacy or a 503B outsourcing facility, is unpublished. | Not published |
| Prescribing model | Skin profile, three photos, photo ID, decision in 24 to 48 hours, no call unless the patient pays $30 for 15 minutes. Providers must be licensed in the patient’s state. | Company-stated |
| Reach and scope | 31 states in a 2021 review, no current list. Terms limit consultations to skin aging and exclude other conditions, including skin cancer. | Independent |
| Pregnancy | A 2021 review states the company will not treat pregnant or nursing women. The approved label records “no adequate and well-controlled studies in pregnant women”. | Public record |
| Commercial traction | YC W18; Target Takeoff Beauty 2021; Beauty Innovation Awards Personalized Skin Care Product of the Year, Nov 2024. Strong retention is founder-claimed, not verified. | Company and award |
Read plainly: a drug with fifty years of literature behind it, delivered through a legal structure written for one patient at a time and now used at subscription scale. That is not by itself a problem, and no FDA action against this company appears in the record. But the two facts that would let an outsider judge the model, the pharmacy’s identity and what the prescriptions document, are both unpublished.
What to watch
- Whether the pharmacy is named, and whether it is a 503A pharmacy or a 503B outsourcing facility. The two carry different duties.
- Any FDA or state board action on personalized topical retinoid compounding.
- Whether the strength ceiling moves again, and whether the reasoning appears.
- A current state list. Thirty-one was a 2021 count.
- The Rx eye serum the founder described, and whether it ships compounded too.
In their words
“All in all, the entire experience wasn’t ideal. It’s inconvenient, inaccessible, costly, and the commercially available retinoids feel medicinal, aren’t tailored to give you a smooth ramp up, and the instructions are horrible.”
Amy Chiu, co-founder and CEO, The Violet Fog, 2020 · Interview
“It was so fun in the early days because we didn’t really know what we were doing.”
Amy Chiu, Brand Architects podcast, Collabs.io, 2025 · Interview
“I just remember thinking on the phone, I think my whole life has changed. My life is about to change and it did.”
Amy Chiu on the Y Combinator acceptance call, Collabs.io, 2025 · Interview
“The first year we weren’t even subscription, which was a huge, I mean, the fact that we weren’t subscription from the get-go, we learned that that is what makes our business.”
Amy Chiu, Collabs.io, 2025 · Interview
“We have a whole list of words that we do not use, that we’ve banned. We don’t use anti-aging. Nowhere in our copy or marketing messaging do we use language like that”
Amy Chiu, Collabs.io, 2025 · Interview
“About 90% of the people I pitched to were men. When I came to them with a dermatology and skincare company, many of them didn’t quite understand the problem.”
Amy Chiu, Attentive, March 2022 · Interview
“I’ve done a lot of research, and this is one of the best anti-aging ingredients you can get”
Fawzia Khan, customer, The New York Times, November 2023 · Independent
Related companies
Sources
- Public recordSection 503A, FD&C Act, 21 U.S.C. 353a
- Public recordCompounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product
- Public recordTretinoin cream USP 0.025% label, ANDA 215713
- Public recordSEC EDGAR searches, Dear Brightly and DermaLoop
- Public recordNSF award 2209408, awardee William Brightly
- IndependentYC-backed DearBrightly makes Rx skin care more accessible
- IndependentI Sent My Doctor a Selfie. Intentionally.
- InterviewBrand Architects: Amy Chiu
- InterviewAn Interview With Dear Brightly Founder Amy Chiu
- InterviewThree founders on moving past no
- IndependentDear Brightly review, 31 state list and earlier formula
- IndependentDearBrightly company profile and news
- PartnerMeet Dear Brightly of Takeoff Beauty
- CompanyDear Brightly FAQ, pharmacy answer and ingredient list
- CompanyTerms of use and Night Shift product page
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
